52 results about "Squamous carcinoma" patented technology

The invention belongs to the technical field of biological medicine, and provides CKS1B serving as an immunotherapy response prediction biomarker and application of the CKS1B, and according to the application, CKS1B serves as an immunotherapy response marker, and a CKS1B inhibitor is combined with an active component to treat a model mouse. In-vitro cell experiments are adopted to evaluate the immunotherapy prediction effect of the CKS1B as a biomarker on esophageal squamous carcinoma, a Cks1b overexpression tumor mouse model, a homologous mouse model and a human immune reconstruction mouse model are established, and a CKS1B inhibitor is combined with active ingredients to treat the two models; results show that the CKS1B inhibitor combined with the active component can promote removal of esophageal squamous carcinoma cells by CD8 + T cells, inhibit interferon signal channels and antigen presentation, effectively recover immune response, inhibit tumor cell proliferation and significantly reduce tumor volume, so as to achieve the purpose of treating esophageal squamous carcinoma.

The application discloses a kind of partition delivery environment response type hydrogel microneedle and its preparation method and application in oral squamous carcinoma treatment.The hydrogel microneedle includes backing layer and the needle tip layer being arranged on the surface of the backing layer, the needle tip layer includes multiple array distribution microneedle tip body, each the needle tip body is connected with the backing layer respectively;Wherein, the backing layer has enzyme response, and the needle tip layer has acidic pH response.The microneedle uses innovative "integration partition design", and two hydrogels with different functions are integrated in single microneedle array: backing layer responds oral flora imbalance microenvironment, needle tip layer responds tumor weak acidic microenvironment.The design can realize partition, accurate, intelligentized synergistic treatment to oral mucosa surface and deep tumor tissue, so as to overcome the technical bottleneck of traditional dosage form in space selectivity, single drug type, release behavior uncontrollable and great systemic toxicity etc.

The invention relates to the technical field of biological medicine, and relates to a polypeptide in targeted combination with SOX2 protein and application thereof, the polypeptide has an amino acid sequence as shown in SEQ ID NO.1, or has at least 85%, 90%, 95% or more than 99% of sequence identity with the amino acid sequence; the polypeptide inhibits phase separation of SOX2, liquid drops formed by phase separation of SOX2 can be avoided, then the situation that the liquid drops wrap chemotherapeutic drugs, influence the curative effect of the chemotherapeutic drugs and cause tolerance of tumor cells to the chemotherapeutic drugs is avoided, and the polypeptide does not influence the transcription activation function of SOX2 serving as a transcription factor; the polypeptide can inhibit the phase separation of the SOX2, so that the regulation of normal physiological functions, such as high expression in organs such as eyes of a human body, of the SOX2 as a transcription factor is not influenced, and therefore, the polypeptide disclosed by the invention can reverse chemotherapy drug resistance of tumors such as squamous carcinoma by inhibiting the phase separation of the SOX2, can be used for adjuvant therapy of the tumors such as squamous carcinoma, and has no obvious toxic or side effect on each organ of an organism.

The invention discloses a novel fusobacterium strain Fusobacteria sp.HPSCC05 and an application of the novel fusobacterium strain Fusobacteria sp.HPSCC05. The preservation number of the novel fusobacterium strain Fusobacteria sp.HPSCC05 is CCTCC (China Center For Type Culture Collection) NO: M2025588. According to the invention, Fusobacterium sp.HPSCC05 derived from hypopharyngeal squamous cell carcinoma tissues is successfully separated, the strain has key technical attributes of stable growth, repeatable culture, clear preservation conditions and the like, and the problem of deficiency of current hypopharyngeal carcinoma related strains is solved. Fusobacteria sp.HPSCC05 is identified as a new fusobacterium species, and the blank of hypopharyngeal carcinoma tumor ecological niche specific strain resources is filled up. The method comprises the following steps: establishing an in-vitro verification model (fusobacterium-hypopharyngeal squamous carcinoma cell co-culture model) of the hypopharyngeal carcinoma promoting effect of the Fusobacterium sp.HPSCC05, and providing a replicable culture mode;

The invention discloses an application of an LAMP1 inhibitor in preparation of a medicine for preventing and / or treating esophageal cancer. Specifically, the application value of the LAMP1 inhibitor Parishin C in esophageal cancer treatment is found and verified for the first time, invasion and metastasis of esophageal squamous carcinoma cells and in-vivo lymph node metastasis can be remarkably inhibited by targeting LAMP1 protein and downstream signal channels of the LAMP1 protein and Parishin C, and a new drug choice is provided for metastatic esophageal cancer lacking effective treatment means clinically.

The application discloses radix sophorae tonkinensis polysaccharide STGP-1, a preparation method thereof and pharmaceutical use for treating lung squamous carcinoma, and relates to the technical field of medicines. The monosaccharide composition of STGP-1 includes fucose Fuc, arabinose Ara, galactose Gal, glucose Glc, xylose Xyl and mannose Man, and the molar ratio is 0.34:12.15:25.76:57.07:1.06:3.62. The STGP-1 is obtained by extraction, separation and purification from dried roots and rhizomes of radix sophorae tonkinensis, and the preparation method comprises the steps of pretreatment and crude extraction, impurity removal treatment, anion exchange column chromatography separation, gel column chromatography purification and the like. The STGP-1 can be used alone or in combination with anti-PD-1 monoclonal antibody for preparing a medicine for treating lung squamous carcinoma. The preparation process is stable, the source is natural, and the STGP-1 can provide a new high-efficiency and low-toxicity candidate medicine for immune combined treatment of lung squamous carcinoma.

The invention provides a lung squamous cell carcinoma organoid culture medium and a culture method. The lung squamous cell carcinoma organoid culture medium is prepared from the following components: R-spondin-1, Noggin, EGF (Epidermal Growth Factor), FGF10 (Fibroblast Growth Factor), FGF7 (Fibroblast Growth Factor), A83-01, Y-27632, Nicotinamide, Insulin, B27 Supplement, N-Acetylcysteine, Alpisib, GlutaMAX, primary cell antibiotics and the like. The lung squamous cell carcinoma organoid culture medium can be used for efficiently culturing lung squamous cell carcinoma tissues and successfully obtaining organoid, the formed organoid is highly similar to primary lung squamous cell carcinoma tissues in cell type, polarity and spatial hierarchical structure, and the micropathologic characteristics of tumors are truly reproduced. And the organoid can be stably passaged for a long time, so that an ideal and reliable preclinical model is provided for pathogenesis research, personalized drug screening and novel therapy development of lung squamous cell carcinoma.

The invention relates to a methylation site marker for assisting in early diagnosis of esophageal squamous cell carcinoma and application of the methylation site marker, and belongs to the technical field of biomedicine. The methylation site marker is one or a combination of human peripheral blood mononuclear cell methylation sites cg05064044, cg03395511 and cg21548813, and the nucleotide sequence of the methylation site marker is as shown in SEQ ID NO. 1-3. According to the present invention, the methylation chip detection results show that the methylation levels of the cg05064044, the cg03395511 and the cg21548813 in the peripheral blood mononuclear cells of the esophageal squamous cell carcinoma patient are significantly increased compared to the health control group; the methylation levels of cg05064044, cg03395511 and cg21548813 sites in PBMC of esophageal squamous cell carcinoma patients in a training queue and a verification queue are all obviously higher than those of a healthy control group through further analysis. Finally, through ROC curve analysis, it is determined that the three methylation sites cg05064044, cg03395511 and cg21548813 have good specificity and sensitivity, have high diagnosis efficiency when being independently or jointly used for esophageal squamous cell carcinoma diagnosis and can be used as potential molecular markers for esophageal squamous cell carcinoma diagnosis.

The invention discloses a marker LGALS9 for diagnosing nasopharyngeal squamous carcinoma and application thereof, and belongs to the technical field of molecular diagnosis. The invention finds that the LGALS9 molecule has significant high expression in nasopharyngeal squamous cell carcinoma tissues, prompts that the LGALS9 can be used as a unique marker for diagnosing the nasopharyngeal squamous cell carcinoma, further constructs a diagnosis model by taking the LGALS9 as the marker, preferably detects the expression level of the marker LGALS9 in the cancer tissues by adopting an immunohistochemical method, and unexpectedly finds that the LGALS9 molecule can be used for diagnosing the nasopharyngeal squamous cell carcinoma tissues. The diagnostic performance of the diagnostic model constructed according to an immunohistochemical detection result is superior to that of a model constructed by adopting a protein spectrum detection method. The marker LGALS9 and the diagnostic model provided by the invention provide technical support for tissue traceability of nasopharyngeal squamous carcinoma, and have great clinical transformation potential.

The invention belongs to the technical field of biological medicines, and particularly relates to application of NLRC5 in targeted screening of medicines for improving immunotherapy of esophageal squamous carcinoma. NLRC5 expression is inhibited or regulated, and immunotherapy of esophageal squamous cell carcinoma is improved. The NLRC5 is highly methylated, and the expression of the NLRC5 in the ESCC is reduced. The NLRC5 is over-expressed, immune cell infiltration is promoted, meanwhile, immune escape is promoted by intensifying T cell depletion, immune checkpoint expression is up-regulated, and an immunosuppression state is created, so that anti-tumor immune response is potentially weakened. The invention discloses a polyhedral function of the NLRC5 in immune regulation and control from a single cell level, and particularly discloses close association of the NLRC5 with an immune checkpoint pathway and T cell depletion. A theoretical basis is provided for developing a therapy for targeting NLRC5, and a new way is possibly opened up for enhancing anti-tumor immune response. Researches show that NLRC5 is an important regulatory factor of immune response in ESCC, and plays a dual role in immune activation and immunosuppression.

The invention discloses a marker LGALS7 for diagnosing nasopharyngeal squamous cell carcinoma and application of the marker LGALS7, and belongs to the technical field of molecular diagnosis. Proteomics screening finds that LGALS7 is remarkably low in expression in nasopharyngeal squamous cell carcinoma tissues, which prompts that LGALS7 can be used as a biomarker for diagnosing nasopharyngeal squamous cell carcinoma. According to the invention, the diagnosis result obtained by detecting the LGALS7 by adopting an immunohistochemical method is higher in accuracy, and a support vector machine model is constructed based on the diagnosis result. A model evaluation result shows that the marker LGALS7 shows relatively high diagnosis specificity and sensitivity in a plurality of independent queues, squamous cell carcinoma from nasopharynx and squamous cell carcinoma from other parts can be effectively distinguished, and the problem of insufficient diagnosis specificity in the prior art is solved.

The invention discloses application of TCM cells in treatment of esophageal cancer. The application finds that the TCM cell can be used for treating esophageal cancer, especially esophageal squamous carcinoma for the first time, a new treatment means is provided for treating esophageal cancer, and the TCM cell has a wide clinical application prospect.

The invention relates to the technical field of biological medicines, in particular to application of a CA9 inhibitor in preparation of a medicine for preventing and treating esophageal squamous carcinoma. The invention provides an application of deoxidized labaquinone in preparation of a CA9 inhibitor, and further provides an application of deoxidized labaquinone or the CA9 inhibitor in preparation of a medicine for preventing and treating esophageal squamous cell carcinoma. According to the application, DEO can be used as a novel CA9 inhibitor, the effect of resisting esophageal squamous cell carcinoma is achieved by inducing alkali death, a brand new theoretical basis is provided for developing the novel inhibitor aiming at CA9 and clinical application of DEO, and the application has important theoretical value and wide clinical application prospects in efficient and low-toxicity treatment of esophageal squamous cell carcinoma.

The invention discloses a biomarker for predicting prognosis of esophageal squamous carcinoma and application of the biomarker, and relates to the technical field of biological medicines. The biomarker is tRF-24, and the nucleotide sequence of the biomarker is as shown in SEQ ID NO. 1. Researches find that the expression of tRF-24 in esophageal squamous cell carcinoma tumor tissues is obviously higher than that in para-carcinoma normal tissues, the expression quantity of late patients is obviously higher than that of early patients, and the higher the expression level is, the shorter the total lifetime of the patients is, and the poorer the prognosis is. Due to the characteristics, the tRF-24 can be used as one of important indexes for judging the clinical outcome of the esophageal squamous carcinoma patient. The invention proves that malignant progression of esophageal squamous carcinoma can be inhibited by reducing the expression quantity of tRF-24, which provides solid theoretical support and experimental basis for targeted therapy of tRF-24.

The invention discloses application of 3-bromo-1H-pyrrole-2, 5-diketone in preparation of a composition for treating esophageal squamous carcinoma, and is characterized in that the molecular formula of the 3-bromo-1H-pyrrole-2, 5-diketone is C4H2BrNO2, the molecular weight of the 3-bromo-1H-pyrrole-2, 5-diketone is 175.97, and the 3-bromo-1H-pyrrole-2, 5-diketone is derived from marine sponge Axinella brevista. The 3-bromo-1H-pyrrole-2, 5-diketone disclosed by the invention can effectively inhibit proliferation, migration, invasion and in-vivo tumor formation of esophageal squamous carcinoma cells, shows extremely low cytotoxicity, is remarkably superior to that of traditional chemotherapeutic drugs, and solves the technical problem that existing drugs for resisting esophageal squamous carcinoma are large in toxic and side effects.

The application relates to the fields of cell biology and biological medicine technology, and specifically discloses a kind of co-culture system construction method based on TGM2 target regulation mesenchymal stem cells and co-culture system prepared by the method. The method comprises the following steps: preparing human umbilical cord mesenchymal stem cells, lung adenocarcinoma cells A549 and lung squamous carcinoma cells SW1573 in logarithmic growth phase respectively; mixing A549 and SW1573 cells according to a 1:1 ratio to obtain mixed lung cancer cells; mixing hUC-MSC and mixed lung cancer cells according to a quantity ratio of 5:1 to 13:1, inoculating in a culture vessel containing culture medium, and culturing at 37 DEG C under a 5% CO2 condition for 3-9 days to obtain the co-culture system. The application does not need to genetically modify hUC-MSC, and by optimizing the co-culture ratio and time, using natural communication between cells, the proliferation, migration and invasion of lung cancer cells can be effectively inhibited, and cell cycle arrest and apoptosis can be induced.

This invention discloses a prognostic model and construction method for cervical squamous cell carcinoma, belonging to the fields of bioinformatics and oncology. The construction method is based on a set of genes related to programmed cell death, integrating multi-omics data of cervical squamous cell carcinoma patients from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and the Cancer Genome Characterization Project (CGCI). After standardized preprocessing, differential expression analysis, bootstrap resampling combined with univariate Cox regression for initial screening, consensus screening using multiple machine learning algorithms, and finally, multivariate Cox proportional hazards regression analysis to identify three core independent prognostic genes and construct a risk scoring model. This model has undergone multi-dimensional validation and optimization, demonstrating robust predictive performance. The method of this invention is standardized and highly reproducible, and the constructed model has high accuracy and strong generalization ability, providing a reliable tool for individualized prognostic assessment and clinical decision-making for cervical squamous cell carcinoma patients.

The invention provides a composition and a kit for oral squamous cell carcinoma typing and application of the composition and the kit, and particularly discloses the composition which comprises a fluorescent staining marker for CBX3 protein and a fluorescent staining marker for IL1RN protein. The invention also discloses a kit containing the composition. The kit and the composition can be used for oral squamous cell carcinoma typing, and prognosis and treatment sensitivity of a patient can be predicted according to a typing structure. The composition and the kit provided by the invention adopt a small amount of genes as classification and prediction indexes, so that the detection cost and the experiment complexity are greatly reduced. Through the established extremely simple classification rule, the expression quantity ratio of CBX3 to IL1RN only needs to be detected through the immunofluorescence technology, sample typing can be rapidly completed according to the condition that CBX3: IL1RN is larger than 1 or smaller than 1, complex biological information analysis is not needed, the detection process is visual and efficient, and the clinical diagnosis efficiency and accuracy can be effectively improved.

The invention belongs to the technical field of molecular markers, and particularly relates to application of FGFBP2 as a lung squamous cell carcinoma diagnosis marker. The invention provides a biomarker for lung squamous cell carcinoma diagnosis, the biomarker is FGFBP2 gene or FGFBP2 protein, the content of the marker in serum of a lung squamous cell carcinoma patient is remarkably increased, the expression level of the marker in lung squamous cell carcinoma tissue is remarkably higher than that of a normal person, and the difference has statistical significance. By detecting the expression level of FGFBP2 in human serum, lung squamous cell carcinoma patients and normal people can be effectively distinguished, and the FGFBP2 can be used for diagnosing lung squamous cell carcinoma.

The application discloses application of a pathogenic transposable element pL1HS as a lung squamous carcinoma biomarker and a therapeutic target. The 5'-UTR region of the pathogenic transposable element pL1HS has a nucleic acid sequence as shown in SEQ ID NO. 1, and specific detection primers are shown in SEQ ID NO. 2 and SEQ ID NO. 3 respectively. Animal experiments prove that the combined application of the reverse transcription transposition inhibitor nevirapine and the cGAS inhibitor can significantly inhibit the growth of lung squamous carcinoma. The pathogenic transposable element pL1HS can be used as a novel molecular marker in the diagnostic application dimension, and provides a precise detection index for early screening, pathological typing and prognosis judgment of lung squamous carcinoma. In the treatment application dimension, the target intervention strategy for pL1HS, especially the combined medication scheme of multi-pathway inhibitors, opens up a new direction.

The invention provides a CA-4 piperazine derivative as well as a preparation method and application thereof, and relates to the field of chemical medicines. The structural formula of the CA-4 piperazine derivative is as shown in formula (1), when R1 is F, R2 is OCH3, and R3 is one of F, Cl, Br, CH3 and OCH3; when R1 is H, R2 is OCH3 or SCH3, and R3 is one of F, Cl, Br, CH3 and OCH3. According to the invention, the Combretastatin A-4 (CA-4) derivative is synthesized and prepared, compounds 32-46 are 15 new compounds, and research finds that the compounds 32-46 have an obvious inhibition effect on 4 tumor cells, and can be applied to preparation of vascular targeting preparation medicines for treating colorectal cancer, lung adenocarcinoma, gastric cancer and lung squamous carcinoma.

The application discloses marker genes for predicting the curative effect of esophageal squamous carcinoma immunotherapy and application thereof. The marker genes comprise a CDC25B gene, an INHBB gene, an ARG1 gene, a CTSW gene, an HSPA2 gene, a TNFRSF9 gene and a LY6E gene. Based on the seven marker genes, the application provides a risk score model for predicting the curative effect of esophageal squamous carcinoma immunotherapy. The risk score model is verified by a ROC curve to have high accuracy and specificity, and can significantly separate patients with high immunotherapy risk from patients with low immunotherapy risk. Compared with existing prediction methods, the application can more accurately predict the pathological remission of esophageal squamous carcinoma patients receiving immunotherapy combined with chemotherapy, and can achieve stable and good prediction effect by using fewer genes, which is beneficial to screening potential immunotherapy benefit patients and making patients benefit better.

The present application relates to the field of pharmaceutical preparations, and particularly relates to application of NQO1 as a target point in preparation of a drug for head and neck squamous cell carcinoma. The present application finds that NQO1 is specifically highly expressed in HNSCC tumor cells, the expression level thereof is significantly negatively correlated with an adverse prognosis of a patient, and NQO1 not only promotes proliferation, migration and in-vivo tumorigenic ability of HNSCC cells, but also participates in regulation of a bithionol death process, which indicates that the NQO1 gene can be used as a key target point for enhancing immunotherapy of HNSCC tumors. In addition, compared with a single-drug treatment group, tumor growth of a mouse in a 'doubled coumarin + anti-PD-L1 antibody' combined treatment group is most effectively inhibited, and the tumor volume and weight are significantly reduced, which first proves that targeted inhibition of NQO1 can significantly sensitize PD-1 / PD-L1 immune checkpoint blocking therapy, and a significant immune synergistic effect is realized in head and neck squamous cell carcinoma. The finding provides an innovative combined treatment strategy and a precise intervention target point for overcoming current clinical problems such as a low response rate and easy drug resistance in immunotherapy of head and neck squamous cell carcinoma.

The invention provides application of a urine protein marker in preparation of a kit for diagnosing esophageal squamous carcinoma. Wherein the urine protein marker is urine Sected photein 1 (SPP1) protein, and researches prove that the SPP1 is highly expressed in urine of esophageal squamous cell carcinoma patients and can be used for detection and auxiliary diagnosis of esophageal squamous cell carcinoma compared with normal control and esophageal squamous cell carcinoma patient groups. According to the invention, the advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of the urine sample are exerted, and SPP1 is detected by using the urine sample.

The application belongs to the field of biomedical technology, and aims to solve the problems of lack of metabolic typing characteristics in the current ESCC molecular typing method, lack of esophageal squamous cell carcinoma molecular typing method based on proteomics and metabolomics, and provides an esophageal squamous carcinoma ESCC molecular typing marker based on DIA proteomics and non-targeted metabolomics and its application. The marker is a combination of 4 proteins and 2 metabolites, the 4 proteins are: hexokinase 3 (HK3), Sec1 family domain protein 1 (SCFD1), septin 5 (SEPTIN5), and signal sequence receptor alpha subunit (SSR1); the 2 metabolites are creatine and 2-deoxy-D-glucose (2'DG). The application fills the gap of the molecular typing method based on proteomics and metabolomics in the field of esophageal squamous carcinoma research, and the proposed molecular typing model can be used as a method for diagnosis, treatment and prognosis evaluation of esophageal squamous carcinoma patients.

The invention relates to the technical field of tongue squamous cell carcinoma cis-platinum chemotherapy treatment, and provides application of a DNPEP inhibitor in preparation of a medicine for reducing the tolerance of cis-platinum to tongue squamous cell carcinoma cells. The DNPEP inhibitor is applied to preparation of the medicine for reducing the tolerance of the cis-platinum to the tongue squamous carcinoma cells, and the tolerance of the tongue squamous carcinoma cells to the cis-platinum is reduced by inhibiting expression of DNPEP in the tongue squamous carcinoma cells. The DNPEP can be used as a treatment target for overcoming the chemotherapy drug resistance of the tongue squamous carcinoma, and the DNPEP inhibitor and cis-platinum are combined for treating the tongue squamous carcinoma, especially for treating patients with cis-platinum resistance type tongue squamous carcinoma.

The application belongs to the technical field of biological medicine, and provides application of gene PTHLH as a target point in auxiliary diagnosis, prognosis judgment and treatment of esophageal squamous carcinoma. The target point PTHLH is an esophageal squamous carcinoma driving target point accumulated based on structural variation TD, that is, a potential target point of a super enhancer accumulated by TD; the super enhancer is an upstream regulation region of PTHLH. The application research finds that the enhancer region of the ESCC driving gene is frequently amplified by TD. These results suggest that the TD event can regulate the related expression of the cancer gene by affecting the gene ontology and the regulation element. Meanwhile, the esophageal squamous carcinoma driving target point accumulated based on the structural variation TD is found to be the potential target point PTHLH of the super enhancer accumulated by TD.

The invention discloses a macaque skin squamous carcinoma cell line MCSCC14397 and application of the macaque skin squamous carcinoma cell line MCSCC14397. The macaque skin squamous carcinoma cell line is named as macaque skin squamous carcinoma cell line MCSCC14397, and the preservation number of the macaque skin squamous carcinoma cell line is CCTCC (China Center For Type Culture Collection) NO: C2025156. The cell line disclosed by the invention has similar protein expression with primary tumor tissues, has chromosome abnormal karyotype, in-vitro tumor formation capability and stable proliferation characteristics, and simultaneously shows remarkable genome instability (such as high-frequency Cgt, T mutation and structural variation) and inflammation signal activation. The MYO10 gene expression in the cell line is up-regulated and drives DNA damage reaction and inflammatory factor expression, and unique advantages are provided for application of the cell line in skin squamous cell carcinoma mechanism research, drug screening and drug efficacy evaluation. The cell line disclosed by the invention can be used as an effective cell model, can be used for establishing a xenotransplantation animal model, and can provide a research basis for deeply researching the occurrence, development, metastasis mechanism and drug resistance mechanism of human skin squamous cell carcinoma as well as innovative drug development and screening.